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INTRODUCTION
Bone marrow transplantation (BMT) and peripheral
blood stem cell (PBSC) transplantation are currently used as
treatments for a variety of malignant and nonmalignant dis-
eases [1]. However, effective use is limited due to serious
and often fatal complications associated with BMT or PBSC
transplantation. In particular, autologous BMT and PBSC
transplantations are associated with a high rate of tumor
relapse, in part due to the original tumor cells contaminat-
ing the bone marrow or peripheral blood and to the lack of
a graft-versus-tumor effect [2,3]. To overcome this obstacle,
different physical, clinical, or immunological means have
been used to purge the contaminating tumor cells ex vivo
[4-6], including the use of activated autologous natural killer
(NK) cells [7,8]. NK cells, initially described as cells with
the ability to kill some tumor cells in a non–major histo-
compatability complex (MHC)-restricted manner, have been
shown to employ various cytotoxic mechanisms, such as
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ABSTRACT
One of the obstacles of BMT that limits its efficacy is failure to eradicate the original tumor. The incidence of tumor
relapse is particularly high after autologous BMT. Natural killer (NK) cells comprise various subsets that can express
inhibitory receptors for MHC class I determinants. We have recently demonstrated that blockade of NK-cell
inhibitory receptors can augment antitumor effects in vitro and in vivo. However, breakdown of tolerance and autore-
activity may occur as a result of the inhibition of NK-cell inactivation to self MHC determinants. We have utilized
F(ab′)2 fragments of monoclonal antibody, 5E6, against Ly49C/I inhibitory receptors, which are expressed on 35% to
60% of NK cells in H2b strains of mice and are specific for H2Kb, to investigate the effect of inhibitory-receptor
blockade on syngeneic bone marrow cell (BMC) and tumor cell growth. We show that treatment of interleukin
2–activated C57BL/6 (B6, H2b) SCID-mouse NK cells with 5E6 F(ab′)2 fragments during 48-hour coculture resulted
in autoreactivity against syngeneic BMCs as demonstrated by suppression of myeloid reconstitution on day 14 post-
BMT. However, this suppressive effect was transient and normalized by day 21 post-BMT. In contrast, blockade of
inhibitory receptors during 24-hour coculture had no adverse effects on myeloid reconstitution after BMT. Further-
more, under the same coculture conditions, NK cell–mediated purging of C1498 leukemia cells contaminating syn-
geneic BMCs was more effective with inhibitory-receptor blockade, leading to a significantly higher proportion of
animals with long-term survival compared to the control recipients. These results demonstrate that short-term in
vitro blockade of inhibitory receptors can augment antitumor activity without long-term inhibitory effects on BMCs
and thus may be of potential use in the purging of contaminating tumor cells prior to autologous BMT.
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perforin/granzyme- or FasL-mediated pathways [9,10]. In
addition, activated NK cells produce cytokines, such as
interferon (IFN)-γ and tumor necrosis factor–α, that medi-
ate antitumor effects [11-13].
NK cells are composed of subsets that are characterized
by the expression of various inhibitory and/or activating
receptors. In mice, these receptors belong to 2 families of
C-type lectins: the Ly49 receptor family speciﬁc for MHC
class I or the CD94/NKG2 receptor family speciﬁc for non-
classical class I, Qa-1 [14,15]. Similarly, human NK-cell
subsets express killer-cell immuoglobulin-like receptors that
are inhibitory and/or activating receptors belonging to
immunoglobulin super family [16] or to the C-type lectin,
CD94/NKG2 [17,18] inhibitory-receptor family. Similar to
the mouse counterpart, these receptors are speciﬁc for HLA
class I molecules [19-21]. Inhibitory receptors contain the
immunoreceptor tyrosine-based inhibitory motif (ITIM) in
the cytoplasmic domains [14,16]. Upon binding of MHC
class I by the inhibitory receptors, phosphorylation of the
tyrosine residue in ITIM occurs, leading to transduction of
inhibitory signals downstream and thus inactivation of the
NK cells [14,16]. On the other hand, activating receptors
lack ITIM in their cytoplasmic domain; instead, they are
associated with an adapter protein, DAP-12, which contains
in its cytoplasmic domain the immunoreceptor tyrosine-
based activating motif (ITAM) [22,23]. It has been shown
that inhibitory signals, which are dominant over activating
signals, usually dictate the functional outcome of NK-cell
subsets [24,25]
Therefore, tumor cells can evade NK cell–mediated
killing by regulating the level of MHC class I expression at
which they can interact with the inhibitory receptors, lead-
ing to inactivation of NK cells. For example, in H2b strains
of mice, 35% to 60% of NK cells express Ly49C/I receptors
speciﬁc for H2Kb molecules [26]; tumor cells bearing H2b
can bind to Ly49C/I inhibitory receptors and inactivate the
subset, which represents a signiﬁcant portion of NK cells.
We have recently demonstrated that blockade of Ly49C/I
inhibitory receptors using F(ab′)2 fragments of antibody
against the inhibitory receptors (5E6) augments antitumor
activity mediated by NK cells both in vitro and in vivo [27].
Therefore, blocking the interaction between inhibitory
receptors and MHC class I on NK and tumor cells, respec-
tively, during the purging procedure may enhance the anti-
tumor effects by blocking NK-cell subset inactivation upon
binding MHC-bearing tumor cells. However, this inhibition
of NK-cell inactivation by blocking receptors specific for
“self” MHC may also result in autoreactivity against
hematopoietic stem cells or progenitors, resulting in failure
of lymphohematopoietic reconstitution. Therefore, it was of
importance to examine whether NK inhibitory-receptor
blockade exerts suppressive effects on the hematopoietic
progenitors and to determine the purging condition in
which the inhibitory-receptor blockade can be used to opti-
mize NK cell–mediated antitumor effects without affecting
hematopoietic cells. In this report, we present data that
demonstrate that blockade of NK inhibitory receptors for
48 hours results in transient suppression of myeloid recon-
stitution after syngeneic BMT. On the other hand, short-
term (ie, 24-hour) blockade of NK inhibitory receptors
during purging of tumor cells can augment NK cell–mediated




C57BL/6 (B6, H2b) and B6.Ly5.2 congenic mice were
obtained from the Animal Production Area (National Can-
cer Institute [NCI]-Frederick, Frederick, MD). Breeding
pairs of B6 severe combined immunodeficient scid/scid
(SCID) mice were generously provided by Dr. Robert H.
Wiltrout (NCI-Frederick), and mice were bred in the NCI-
Frederick animal facility. All mice were kept in a specific
pathogen-free condition and used at 8 to 14 weeks of age.
Antibodies and Generation of F(ab′)2 Fragments
Fluorescein isothiocyanate (FITC)-conjugated CD45.1,
and CD45.2 were purchased from Pharmingen (San Diego,
CA), and F(ab′)2 fragments of normal mouse immunoglobu-
lin (Ig) G (NMG) were purchased from Jackson Immuno-
Research (West Grove, PA). F(ab′)2 fragments of anti-
Ly49C/I (5E6, mouse IgG2a) and anti-Ly49G2 (4D11, rat
IgG2a; the hybridoma, a gift from Dr. John Ortaldo, NCI-
Frederick) monoclonal antibodies (MoAbs) were prepared
as previously described [22]. The purity of F(ab′)2 fragments
was determined by sodium dodecyl sulphate–polyacrylamide
gel electrophoresis.
Cell Lines
C1498 (H2b), a murine leukemia cell line, was obtained
from American Type Culture Collection (Rockville, MD),
and the bulk culture of C1498 cells were kept in log phase
of growth for 7 days and frozen for later use. Frozen stocks
were thawed every 2 months for in vitro assays. For in vivo
experiments, frozen stocks were freshly thawed 7 to 10 days
prior to in vivo administration and were kept in log phase of
growth until use.
SCID NK-Cell Culture
Splenocytes and BMCs from B6 SCID mice were cul-
tured in NK-cell media (RPMI 1640 supplemented with
10% fetal bovine serum [FBS], 100 units/mL penicillin/
streptomycin, 50 µg/mL gentamycin, 2 mmol/L L-glutamine,
10 mmol/L HEPES (N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid), 1 mmol/L nonessential amino acids,
1 mmol/L sodium pyruvate, 2.5 × 10–5 mol/L 2-mercapto-
ethanol (ME), and 1 µg/mL indomethacin) containing 5000
IU/mL recombinant human interleukin-2 (rhIL-2; Devel-
opmental Therapeutics Program, NCI-Frederick) at 0.5 ×
106 cells/mL for splenocytes or 1 × 106 cells/mL for BMCs
for 5 to 7 days. These IL-2–activated SCID splenocytes and
BMCs were >97% NK1.1+
NK + BMC Cocultures and Colony Assays
B6 BMCs (5 × 105) were cultured with B6 SCID NK
cells at an NK cell–to-BMC ratio (NK:BMC) of 1:1, 1:5, or
1:10 in Iscove’s Modified Dubecco’s Medium (IMDM)
supplemented with 10% FBS, 5 × 10–5 mol/L 2-ME, and
100 u/mL penicillin/streptomycin (10% IMDM) with
5000 IU/mL rhIL-2 in 24-well plates for 24 or 48 hours. In
some experiments, 3 × 107 IL-2–activated NK cells were
Effects of NK Inhibitory-Receptor Blockade on Hematopoietic Cells
19B B & M T
treated with 300 µg of F(ab′)2 fragments of NMG, 5E6, or
4D11 for 2 hours in the presence of 5000 IU/mL rhIL-2
prior to coculture with the equal number of BMCs (ﬁnal anti-
body concentration at 25 µg/mL) in 10% IMDM containing
5000 IU/mL rhIL-2 in T-25 flasks. The cocultured cells
were collected, and aliquots of BMCs were transferred into
colony-assay media (IMDM containing 25% FBS, 100 u/mL
penicillin/streptomycin, 2 mmol/L L-glutamine, 5 × 10–5
mol/L 2-ME, 10 ng/mL recombinant murine granulocyte-
macrophage colony-stimulating factor [rmGM-CSF]
[AMGen Corporation, Thousand Oakes, CA], rmIL-3
[Developmental Therapeutics Program, NCI-Frederick],
and 1.1% methylcellulose [wt/vol]) so that 5 × 104 BMCs
(based on the cell number at the initiation of the cocultures)
could be plated per 35-mm Petri dish in triplicates. Cultures
were incubated for 7 days in humidiﬁed atmosphere at 37°C
with 5% CO2. At day 7, colonies were enumerated on a
stereo microscope (Nikon, Melville, NY). The coculture con-
ditions were critical to obtain consistent results between in
vitro colony assays and hematopoietic reconstitution in vivo.
Hematopoietic Reconstitution Studies
For experiments assessing the effects of NK cells on
BMCs, 3-6 × 107 B6 SCID NK cells were preincubated with
300-500 µg of F(ab′)2 fragments of NMG, 5E6, or 4D11 in
2-3 mL 10% IMDM at 37°C for 2-3 hours in the presence of
5000 IU/mL rhIL-2. BMCs were prepared from B6 or
B6.Ly5.2 mice and cultured either alone or with the F(ab′)2
fragment–treated NK cells (BMC:NK = 1:1 and ﬁnal concen-
tration of antibody at 25 µg/mL) in 10% IMDM in the
presence of 5000 IU/mL rhIL-2 for 24 or 48 hours. The
cocultured cells were then harvested and resuspended in Dul-
becco’s Phosphate Buffered Saline (DPBS) to be used in the
colony assay, as described above, and for injection into the
animals. B6 recipients were lethally irradiated at 8.5 Gy and
infused with the cells at 3-5 × 106 BMCs and 3-5 × 106 NK
cells per mouse (IV), based on the cell numbers at the initia-
tion of the coculture. At various days post-BMT, splenocytes
and BMCs were prepared from 3 to 4 mice per group and
were used in colony assays to determine myeloid reconstitu-
tion as described above. Peripheral blood samples were col-
lected in ethylene diamine tetraacetic acid (EDTA)-treated
Microtainer tubes (Becton Dickinson, San Jose, CA). Red
blood cell (RBC) and white blood cell (WBC) counts were
determined by analyzing the blood samples on the
HEMAVET Multispecies Hematology Analyzer (CDC Tech-
nologies, Oxford, CT). In the experiments using B6.Ly5.2
congenic mice as donors, the level of donor chimerism was
determined at day 98 post-BMT by staining splenocytes and
BMCs with FITC-conjugated anti-mouse CD45.1 or
CD45.2 and analyzing on a ﬂuorescence-activated cell sorter
(FACScan; Becton Dickinson, San Diego, CA).
Ex Vivo Purging of Tumor and Survival Studies
For purging of tumor cells, 2 × 107 or 3 × 107 B6 SCID
NK cells were pretreated with 300 µg of 5E6 or 4D11
F(ab′)2 fragments for 2 to 3 hours. NK cells were cultured
further with 3 × 107 B6 BMCs and 2 × 105 or 3 × 105 C1498
cells (NK:BMC = 1:1 or less, NK:C1498 = 100:1, and ﬁnal
concentration of antibody at 25 µg/mL) for 24 hours. The
cocultured cells were then harvested and injected into
lethally irradiated (8.5 Gy) B6 recipient mice (8-10 mice per
group per experiment) at 3 × 106 BMCs, 2-3 × 106 NK cells,
and 2-3 × 104 C1498 cells per mouse (IV), based on the cell
numbers at the initiation of cocultures. Mice were then mon-
itored for survival. In addition, aliquots of the cocultured
cells were transferred into colony-assay media without
rmGM-CSF and rmIL-3 for colony assay as described above.
Statistics
Nonparametric analysis of one-way variation (ANOVA)
with Newman-Keuls test was used for in vitro assays, and
log-rank test was used for survival studies.
RESULTS
NK Cells Can Exert Inhibitory Effects on BMCs
During Cocultures
Although exposure of tumor cells contaminating the
bone marrow to large numbers of activated NK cells would
be more effective in eliminating the tumor cells, NK cells
may have deleterious effects on BMCs because of cytokines,
such as IFN-γ, that have been shown to inhibit the growth
of BMCs in some in vitro studies [2,28]. To determine under
what condition NK cells alone can have inhibitory effects on
syngeneic BMCs, B6 BMCs were cocultured with IL-2–
activated NK cells derived from B6 SCID mice at an
NK:BMC of 10:1, 5:1, or 1:1 for 24 hours. Cocultured cells
were then transferred into semisolid media containing
rmGM-CSF and rmIL-3 and cultured further for 7 days. As
shown in Figure 1A, the growth of granulocyte/monocyte
progenitors (colony-forming units [CFU]-GM) was signiﬁ-
cantly inhibited in the cocultures with higher NK cell–to-
BMC ratios compared to that of the control BMCs that
were cultured alone, such that no colonies could be detected
in the cocultures with NK:BMC = 10:1. However, the num-
ber of CFU-GM from the cocultures of NK:BMC = 1:1 was
not affected in 24 hours compared to the BMC-only control
culture. Because an optimal condition for purging of tumor
cells contaminating BMCs may require coculture with NK
cells for longer than 24 hours, the effect of NK cells on
BMCs at NK:BMC = 1:1 was further examined in 48-hour
coculture studies. The results show that growth of granulo-
cyte/monocyte progenitors was significantly but not com-
pletely inhibited by NK cells in 48-hour cocultures compared
to that of the BMC-only control cultures (Figure 1C)
whereas growth of granulocyte/monocyte progenitors was
not affected in 24 hours. BMCs derived from B6 mice
express an MHC class I molecule, H2Kb, that is a speciﬁc
ligand for inhibitory receptors, Ly49C/I, present on a subset
of NK cells. Cross-linking of the inhibitory receptors by
these class I ligands present on tumor cells may inactivate
the subset of NK cells expressing Ly49C/I. We have previ-
ously shown that blockade of Ly49C/I with F(ab′)2 frag-
ments of the 5E6 MoAb speciﬁc for the receptor augments
antitumor effects in vitro [27]. However, by this same mech-
anism, blockade of NK inhibitory receptors to self MHC
molecules may increase autoreactivity to hematopoietic
cells. To assess whether blockade of NK inhibitory receptors
has any adverse effects on BMCs, IL-2–activated B6 SCID
NK cells were pretreated with media or F(ab′)2 fragments of
NMG, 5E6, or 4D11 MoAbs. 4D11 is a MoAb speciﬁc for
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the Ly49G2 receptor, which is expressed on 50% to 60% of
NK cells. It binds to MHC H2Dd [22] but not to H2Kb
(Table 1) and thus was used as an irrelevant control antibody
in the cocultures of NK cells and BMCs derived from B6
(H2b) mice. F(ab′)2 fragments were used to ensure blockade
of the inhibitory receptors without activation via FcγR in
vitro during the coculture and depletion of the antibody-
binding subset in vivo. Pretreated NK cells were then cul-
tured with BMCs for 24 or 48 hours, after which survival of
hematopoietic progenitors was assessed in colony assays.
The results indicate that blockade of neither Ly49C/I nor
Ly49G2 inhibitory receptors during the 24-hour cocultures
suppressed the level of CFU-GM compared to control
BMCs cultured with NMG F(ab′)2–treated NK cells (Figure
1B). Similarly, treatment of NK cells with 5E6 or 4D11
F(ab′)2 fragments did not result in further suppression of
granulocyte/monocyte growth in 48 hours compared to that
of the control cocultures (Figure 1C), suggesting that block-
ade of inhibitory signals in NK + BMC cocultures does not
decrease the growth of granulocyte/monocyte progenitors
to a greater extent than does the inhibition mediated by
untreated NK cells in vitro.
Inhibitory-Receptor Blockade During 24-Hour NK +
BMC Coculture Does Not Affect Hematopoietic
Reconstitution In Vivo
Although no deleterious effects of NK inhibitory-
receptor blockade on BMCs were observed in a short-term
in vitro assay examining the growth of granulocyte/mono-
cycte progenitors, NK cells may have affected the ability of
BMCs to reconstitute in vivo after BMT. Therefore, we
examined the ability of BMCs that were cocultured with
NK cells with or without inhibitory-receptor blockade to
repopulate lethally irradiated syngeneic recipients after
BMT. In addition, to assess the long-term donor chimerism
after syngeneic BMT, we used BMCs from B6 mice that are
congenic for Ly5.2 (CD45.1)-antigen expression, which can
be distinguished by flow cytometric analysis from Ly5.1
(CD45.2) antigen expressed by the conventional host B6
mice. B6.Ly5.2 BMCs were cultured either alone or with
activated B6 SCID NK cells pretreated with F(ab′)2 frag-
ments of NMG, 5E6, or 4D11 at NK:BMC = 1:1 for
24 hours, and lethally irradiated B6 recipient mice were
infused with the cocultured BMCs. At days 7, 14, 21, and
27 post-BMT, the level of myeloid reconstitution was
determined using splenocytes and BMCs in colony assays.
The results indicate that neither NK cells alone nor those
with blockade of Ly49C/I inhibitory receptors had any
adverse effects on myeloid reconstitution in spleen and
bone marrow compared to that in the control mice at all
time points post-BMT (Figure 2). Additionally, there was
no difference in reconstitution of mature RBCs and WBCs,
as determined by RBC and WBC counts in peripheral
blood (data not shown). To determine the effect of
Ly49C/I-receptor blockade on long-term donor chimerism,
Figure 1. Effect of NK cells and inhibitory-receptor blockade on syn-
geneic BMCs in vitro. B6 BMCs (5 × 105) were cultured with IL-2–
activated B6 SCID NK cells at a NK cell–to-BMC ratio of 1:1, 1:5, or 1:10
in 10% IMDM containing 5000 IU/mL rhIL-2, for 24 hours (A). IL-
2–activated NK cells (3 × 107) were treated with 300 µg of F(ab′)2 frag-
ments of NMG, 5E6, or 4D11 for 2 hours in the presence of 5000 IU/mL
rhIL-2 prior to coculture with 3 × 107 BMCs (NK:BMC = 1:1 and ﬁnal
concentration of antibody at 25 µg/mL) in 10% IMDM containing
5000 IU/mL rhIL-2, for 24 (B) or 48 (C) hours. The cocultured cells
were collected, and aliquots of BMCs were transferred into colony-assay
media containing 1.1% methylcellulose and 10 ng/mL of rmGM-CSF
and rmIL-3 so that 5 × 104 BMCs (based on the cell number at the initia-
tion of the cocultures) could be plated per 35-mm Petri dish in triplicates.
The cells were incubated for 7 days in humidiﬁed atmosphere at 37°C
with 5% CO2, and the number of colonies were counted. Mean values of
the triplicates ± SEM from a representative of 3 (A and B) or 4 (C) inde-
pendent experiments are shown. Nonparametric ANOVA with Newman-
Keuls multiple-group comparison test was used for statistical analysis.
ND indicates none detected.
Table 1. Ly49 Family of Receptors and the Ligands
Category Receptors Ligands MoAb*
Inhibitory Ly49A H2Dd YE1/32
Ly49C/I H2Kb 5E6
Ly49G2 H2Dd 4D11
Activating Ly49D H2Dd 4E5
Ly49H ? 1F8
*Monoclonal antibodies speciﬁc for Ly49 receptors.
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splenocytes from the recipient mice were analyzed for the
levels of donor-cell engraftment, as demonstrated by Ly5.2-
antigen expression at day 98 post-BMT. The levels of
donor chimerism were comparable in all recipients regard-
less of the coculture conditions (Table 2), demonstrating
that the ability of BMCs to reconstitute lethally irradiated
hosts is not affected by blockade of NK inhibitory receptors
during a 24-hour coculture period.
Suppressive Effects of NK Cells on BMCs in 48-Hour
Cocultures Result in Short-Term Inhibition of Myeloid
Reconstitution In Vivo
In contrast to the 24-hour cocultures of NK cells and
BMCs, culturing of BMCs with NK cells for 48 hours
resulted in a signiﬁcant decrease in the numbers of CFU-
GM compared to the control culture in vitro. Thus, whereas
BMCs in the 24-hour cocultures were not altered in their
ability to reconstitute lethally irradiated syngeneic recipi-
ents, the adverse effects of NK cells on BMCs observed in
48-hour cocultures may result in suppression of hemato-
poietic reconstitution in vivo. To address this, NK cells were
pretreated with the F(ab′)2 fragments of NMG, 5E6, or
4D11 and cocultured with BMCs for 48 hours. Lethally
irradiated B6 mice were then injected with the cocultured
cells, and at days 7, 14, 21, and 28 post-BMT, the effects on
myeloid reconstitution of the recipients were examined. The
results show that the levels of myeloid reconstitution were
significantly decreased in the spleen (P < .001) and bone
marrow (P < .001) (Figure 3) of mice receiving cells from
NK + BMC cocultures at day 7 post-BMT compared to that
of the control mice receiving BMCs cultured alone. The
extent of suppression of myeloid reconstitution at day 7
post-BMT was not signiﬁcantly different among the treat-
ment groups, correlating with the in vitro assays. At day 14
post-BMT, the suppression of myeloid reconstitution in
mice receiving BMCs cultured with NMG F(ab′)2- or 4D11
F(ab′)2-treated NK cells was normalized such that, in the
spleen, the level of myeloid reconstitution was comparable
to that of the control mice that underwent transplantation
with BMCs cultured alone (Figure 3). More importantly,
myeloid reconstitution was signiﬁcantly suppressed in both
the spleen (P < .01) and bone marrow (P < .001) of only
those mice receiving BMCs cultured with NK cells that
were preincubated with 5E6 F(ab′)2 fragments and not with
4D11 F(ab′)2 fragments, suggesting that even though further
inhibition of CFU-GM growth due to inhibitory-receptor
blockade was not observed in vitro, the ability of hemato-
poietic precursors to reconstitute lethally irradiated recipi-
ents was suppressed by inhibition of NK-cell inactivation by
the receptor blockade. However, the results indicate that the
inhibition of myeloid reconstitution was transient, in that by
day 28 post-BMT the levels of CFU-GM were comparable
among all groups. Assessment of reconstitution of periph-
eral blood cells indicates that, whereas NK cells exerted sup-
pressive effects on neutrophil and platelet recovery tran-
siently at day 14 post-BMT, inhibitory-receptor blockade
did not result in additional inhibition (Figure 4).
Figure 2. Effect of inhibitory-receptor blockade during 24-hour
coculture on myeloid reconstitution after BMT. B6 SCID NK cells
(3 × 107) were preincubated with 300 µg of F(ab′)2 fragments of
NMG, 5E6, or 4D11 in 10% IMDM at 37°C for 2 to 3 hours in the
presence of 5000 IU/mL rhIL-2. BMCs from B6.Ly5.2 mice were cul-
tured either alone or with the F(ab′)2-treated NK cells (BMC:NK =
1:1 and ﬁnal concentration of antibody at 25 µg/mL) in 10% IMDM
in the presence of 5000 IU/mL rhIL-2 for 24 hours. At 24 hours, B6
recipients were lethally irradiated at 8.5 Gy and infused with the
cocultured cells at 3 × 106 BMCs and 3 × 106 NK cells per mouse
(IV), based on the cell numbers at the initiation of the coculture. At
various days post-BMT, colony assays were performed using spleno-
cytes and BMCs (4 mice/group) to determine myeloid reconstitution
in spleen (A) and bone marrow (B). A representative of 2 independent
experiments is shown as mean ± SEM. Nonparametric ANOVA with
Newman-Keuls multiple-group comparison test was used for statisti-
cal analysis. The mean values of the various groups were not signifi-
cantly different (P > .05).
Table 2. Effect of Ly49C/I-Receptor Blockade on Expression of Ly5.2 
Antigen in Spleen
Treatment* No. of Mice % Donor Chimerism†
No NK 3 95 ± 0.4‡
NK+NMG 3 94 ± 0.4
NK+5E6 3 94 ± 0.3
NK+4D11 3 95 ± 0.2
*B6 SCID NK cells were pretreated with F(ab′)2 fragments of
NMG, 5E6, or 4D11 MoAbs prior to the cocultures with donor
B6.Ly5.2 BMCs.
†At day 98 post-BMT, splenocytes from mice were incubated with
either FITC–anti-Ly5.1 (host) or anti-Ly5.2 (donor) MoAb and ana-
lyzed on FACScan.
‡The numerical values represent Ly5.2+ cells as percent lympho-
cytes ± SEM.
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Blockade of Ly49C/I Receptors Augments Purging
Effects of NK Cells Against Contaminating Tumor
Cells in H2b Mice
Because activated NK cells, with or without inhibitory-
receptor blockade, did not have any deleterious effects on
BMCs in 24-hour cocultures at NK:BMC = 1:1 in vitro as
well as in vivo, blockade of NK inhibitory receptors under
the same conditions may result in increased antitumor
effects against syngeneic tumor cells without affecting
BMCs. To determine whether NK cell–mediated purging of
tumor is enhanced under these coculture conditions, IL-2–
activated B6 SCID NK cells were pretreated with F(ab′)2
fragments of 5E6 or 4D11 and cocultured with B6 BMCs
(NK:BMC = 1:1) contaminated with C1498 leukemia cells
(NK:tumor = 100:1) for 24 hours. The cells from the cocul-
tures were used in colony-formation assays to assess the
effects of Ly49C/I blockade on antitumor activity. As shown
in Figure 5A, the growth of C1498 tumor cells was signiﬁ-
Figure 3. Effect of inhibitory-receptor blockade during 48-hour
coculture on myeloid reconstitution after BMT. B6 SCID NK cells
(6 × 107) were preincubated with 500 µg of F(ab′)2 fragments of NMG,
5E6, or 4D11 in 10% IMDM at 37°C for 2 to 3 hours in the presence
of 5000 IU/mL rhIL-2. BMCs from B6 mice were cultured either
alone or with the F(ab′)2-treated NK cells (BMC:NK = 1:1 and ﬁnal
concentration of antibody at 25 µg/mL) in 10% IMDM in the presence
of 5000 IU/mL rhIL-2 for 48 hours. At 48 hours, B6 recipients were
lethally irradiated at 8.5 Gy and infused with the cocultured cells at 5 ×
106 BMCs and 5 × 106 NK per mouse (IV), based on the cell numbers
at the initiation of the coculture. At various days post-BMT, colony
assays were performed using splenocytes and BMCs (3-4 mice/group)
to determine myeloid reconstitution in spleen and bone marrow. A rep-
resentative of 3 independent experiments is shown as mean ± SEM.
Nonparametric ANOVA with Newman-Keuls multiple-group compar-
ison test was used for statistical analysis.
Figure 4. Effect of inhibitory-receptor blockade during 48-hour
coculture on recovery of RBCs and leukocytes after BMT. B6-SCID
NK cells (6 × 107) were preincubated with 500 µg of F(ab′)2 fragments
of NMG, 5E6, or 4D11 in 10% IMDM at 37°C for 2 to 3 hours in the
presence of 5000 IU/mL rhIL-2. BMCs from B6 mice were cultured
either alone or with the F(ab′)2-treated NK cells at (BMC:NK = 1:1
and ﬁnal concentration of antibody at 25 µg/mL) in 10% IMDM in the
presence of 5000 IU/mL rhIL-2 for 48 hours. At 48 hours, B6 recipi-
ents were lethally irradiated at 8.5 Gy and infused with the cocultured
cells at 5 × 106 BMCs and 5 × 106 NK cells per mouse (IV), based on
the cell numbers at the initiation of the coculture. At various days post-
BMT, peripheral blood was collected (3-4 mice/group) in EDTA-
treated Microtainer tubes and analyzed by HEMAVET multispecies
hematology analyzer to determine the neutrophil (A), RBC (B), and
platelet (C) counts. A representative of 2 independent experiments is
shown as mean ± SEM. Nonparametric ANOVA with Newman-Keuls
multiple-group comparison test was used for statistical analysis.
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cantly decreased in the presence of NK cells treated with
4D11 F(ab′)2 in 24 hours (P < .0001, 95% inhibition) com-
pared to that of the tumor-only control. Moreover, greater
inhibition of the tumor cell growth was observed when NK
cells were treated with 5E6 F(ab′)2 (99% inhibition com-
pared to the that of the tumor-only control), and this effect
was 5E6 F(ab′)2 speciﬁc, as demonstrated by a lack of such
inhibition when 4D11 F(ab′)2-treated NK cells were used in
the cocultures (P < .001). When the cocultured cells were
used in the BMT of lethally irradiated B6 mice, the groups
injected with C1498-contaminated BMCs cultured with the
control antibody, 4D11 F(ab′)2-treated NK cells survived
significantly longer than did the BMC and tumor-only
control groups (P < .0001) (Figure 5B). More importantly,
mice receiving tumor-contaminated BMCs cultured
with 5E6 F(ab′)2-treated NK cells survived significantly
longer than those receiving tumor-contaminated BMCs cul-
tured with NK cells and the control 4D11 F(ab′)2 fragments
(P = .0417) (Figure 5B). Surviving mice had normal hemato-
poietic reconstitution, as measured by various hematopoietic
parameters (data not shown). These results demonstrate that
under appropriate conditions, blockade of inhibitory recep-
tors suppresses the inactivation of NK cells and augments
antitumor activity without long-term deleterious effects on
myeloid reconstitution after BMT.
DISCUSSION
The use of autologous BMT as a therapy for cancer is
limited because of a higher relapse rate that can result from
tumor cells contaminating the bone marrow [7,8]. Previous
studies have demonstrated the potential of activated autolo-
gous NK cells for purging of the contaminating tumors
prior to BMT to improve its efficacy [2,3]. However, the
purging effect mediated by autologous NK cells may be
hampered by the inhibitory receptors expressed on the sub-
set of NK cells [14,16]. The missing self hypothesis states
that NK cells are in an activated state unless they interact with
the self MHC class I and receive negative signals via the
inhibitory receptors [29]. Expression of at least 1 inhibitory
receptor speciﬁc for self MHC class I may prevent NK cells
from autoreactivity but also minimizes cytotoxicity against
the tumor cells that express the same determinant or ligands
for activating receptors. In this study, we show that under
certain conditions blockade of NK-cell inhibitory receptors
augments purging effects against syngeneic tumor cells
contaminating BMCs without inducing signiﬁcant autoreac-
tivity to “self” hematopoietic cells (Figure 2). However,
inhibitory-receptor blockade can result in significant sup-
pression of syngeneic BMCs, depending on the conditions
used for NK + BMC cocultures (Figure 3).
Previous studies indicated that NK cells alone can have
different effects on BMCs, depending on the conditions in
which the BMCs are placed. If the culture conditions are
suboptimal for hematopoietic progenitor growth, then
cytokines such as GM-CSF, G-CSF, and IL-1β produced by
activated NK cells can promote the growth of BMCs [12,28].
However, if the culture conditions are optimal for growth of
hematopoietic progenitors, then NK cells mediate inhibitory
effects partially via the production of IFN-γ [12]. These
observations are consistent with the increased suppression of
the level of CFU-GM in the presence of increasing numbers
of NK cells (Figure 1). In addition, the results demonstrate
that the duration of exposure of BMCs to syngeneic NK cells
can determine the extent of inhibition on BMCs, because the
growth of CFU-GM in vitro was suppressed after 48-hour
coculture, even at an NK cell–to-BMC ratio that had no
inhibitory effect in 24 hours. Similarly, NK cell–mediated
suppressive effects on myeloid progenitors, due to
inhibitory-receptor blockade, could be observed in vivo,
albeit transiently, only if NK cells and BMCs cocultured with
5E6 F(ab′)2 fragments for 48 hours, but not 24 hours, were
used in BMT (Figure 2 and 3). Therefore, the results indi-
cate that a balance between these factors is essential to opti-
mize the hematopoietic recovery with effective abrogation of
tumor cells contaminating the bone marrow.
It is interesting that whereas in vitro growth of CFU-
GM from BMCs cocultured with 5E6 F(ab′)2–treated NK
Figure 5. Effect of blockade of Ly49C/I receptors on purging C1498
cells. IL-2–activated B6 SCID NK cells (3 × 107) were pretreated with
300 µg of 5E6 or 4D11 F(ab′)2 fragments for 2 to 3 hours. NK cells
were cultured further with 3 × 107 B6 BMCs and 3 × 105 C1498 cells
(NK:BMC = 1:1, NK:C1498 = 100:1, and ﬁnal concentration of anti-
body at 25 µg/mL) for 24 hours. At 24 hours, aliquots of the cocultured
cells were transferred into colony-assay media without exogenous
cytokines so that 100 or 1000 C1498 cells (based on the cell number at
the initiation of the coculture) are plated per Petri dish in triplicate to
enumerate C1498 colonies in vitro (A). A representative of 2 indepen-
dent experiments is shown as mean ± SEM, and nonparametric
ANOVA with Newman-Keuls multiple-group comparison test was
used for statistical analysis. Lethally irradiated (8.5 Gy) B6 mice were
injected with the cocultured cells at 3 × 106 BMCs, 3 × 106 NK, and 3 ×
104 C1498 cells per mouse (IV), based on the cell numbers at the initia-
tion of cocultures, and were monitored for survival (B). Pooled data
from 2 independent experiments is shown (n = 18 per group), and the
log-rank test was used for statistical analysis.
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cells for 48 hours was not inhibited compared to that of
control BMCs cocultured with NMG F(ab′)2– or 4D11
F(ab′)2–treated NK cells, myeloid reconstitution of mice
that underwent transplantation with these cocultures was
impaired only in the group that received BMCs cocultured
with 5E6 F(ab′)2–treated NK cells. Moreover, 5E6 F(ab′)2
treatment resulted in suppression of early myeloid reconsti-
tution without affecting mature hematopoietic parameters
in the peripheral blood (Figure 4). It may be that the block-
ade of inhibitory receptors allows NK cells to exert greater
suppressive effects selectively on myeloid progenitors. Pre-
sumably, every NK cell has at least 1 inhibitory receptor to
self MHC class I to prevent autoreactivity, but in the
absence of inhibitory signal, an activating receptor, which
has been shown to play a critical role in NK response to
murine cytomegalovirus infection [30-32], may play a role
in the selective myelosuppression. The mechanism of NK
cell–mediated suppressive effects due to inhibitory-receptor
blockade is yet to be deﬁned; it may be due to direct cyto-
toxicity against myeloid progenitors or indirect effects by
increased production of inhibitory cytokines (ie, IFN-γ)
[33,34]. Although the NK cell–mediated suppressive effects
on myeloid progenitors is transient in this model in which
total BMCs are used, the selective inhibition of myeloid
reconstitution due to inhibitory-receptor blockade may be
more severe, even in a short-term coculture period, if a
puriﬁed population such as CD34+ cells [3,6] is used in the
purging process and BMT.
We have recently reported that adoptive transfer of acti-
vated NK cells treated with 5E6 F(ab′)2 ex vivo into C1498
tumor–bearing mice signiﬁcantly increases the rate of sur-
vival compared to that of the control-treated mice [27]. The
current study further demonstrates that blockade with 5E6
F(ab′)2of Ly49C/I inhibitory receptors during in vitro purg-
ing of C1498 leukemia–contaminating BMCs significantly
augments the antitumor effects mediated by NK cells. In
addition, the results indicate that the enhanced antitumor
effects can be achieved without inducing signiﬁcant autore-
activity as evidenced by myelosuppression. The reduction in
tumor growth in vitro and the increase in the survival of
mice that received transplants of purged BMCs in the pres-
ence of 5E6 F(ab′)2, but not 4D11 F(ab′)2 (the irrelevant
antibody control specific for Ly49G2 present on 50% to
60% of NK cells but does not interfere with binding of H2b
[Figure 5]), were observed under the same coculture condi-
tion in which no adverse effects on hematopoietic reconsti-
tution resulted in vivo.
The suppressive effect of NK inhibitory-receptor block-
ade during 48-hour coculture was transient and did not
affect reconstitution of peripheral blood cells. Thus, varia-
tions of purging conditions such as prolonging the period of
purging or blockade of multiple inhibitory receptors speciﬁc
for self MHC class I to eradicate resistant tumor cells
should be attempted with caution to determine whether the
beneﬁts of increased antitumor activity outweigh the poten-
tial harmful effects on hematopoietic reconstitution. This
study demonstrates that, taken together, blockade of
inhibitory receptors on activated NK cells during in vitro
purging of syngeneic tumors and after BMT with the in
vitro–purged BMCs will provide another avenue to increase
antitumor activity mediated by NK cells without signiﬁcant
autoreactivity. Therefore, NK inhibitory-receptor blockade
can be of potential use to increase the efﬁcacy of autologous
BMT as a means of cancer therapy.
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